Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd

Link copied
Case Copied 73 min read

FEDERAL COURT OF AUSTRALIA

Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2012] FCA 1510

Citation: Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2012] FCA 1510
Parties: BAYER PHARMA AKTIENGESELLSCHAFT and BAYER AUSTRALIA LIMITED (ACN 000 138 714) v GENERIC HEALTH PTY LTD (ACN 110 617 859) and LUPIN AUSTRALIA PTY LIMITED (ACN 112 038 105)
File number: NSD 236 of 2012
Judge: YATES J
Date of judgment: 14 December 2012
Catchwords: PATENTS – patent amendment application – whether discretion under s 105 of the Patents Act 1990 (Cth) should be exercised in favour of making the amendments sought – consideration of whether unreasonable delay, covetous claiming or unfair advantage present
Legislation: Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)
Patents Act 1990 (Cth) ss 40, 102, 105, 122, 123
Federal Court Rules 2011 (Cth) r 34.41
Cases cited:

Apotex Pty Ltd v Les Laboratoires Servier (No 2) (2009) 83 IPR 42
Apotex Pty Ltd v Les Laboratoires Servier (No 3) [2009] FCA 1069
Autoliv Development AB’s Patent [1988] RPC 425
Bristol-Myers Squibb Co v Apotex Pty Ltd (2010) 87 IPR 516
CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 3) [2010] FCA 1279
CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) (2010) 190 FCR 522
Gambro Pty Ltd v Fresenius Medical Care South East Asia Pty Ltd [2000] FCA 407
Gedeon Richter plc v Bayer Schering Pharma AG [2011] EWHC 583 (Pat)
ICI Chemicals & Polymers Ltd v Lubrizol Corp (1999) AIPC 91-521
Imperial Chemical Industries Ltd (Whyte’s) Patent [1978] RPC 11
Les Laboratoires Servier v Apotex Pty Ltd (2010) 273 ALR 630
Lockwood Security Products Pty Limited v Doric Products Pty Limited (2004) 217 CLR 274
Novartis AG v Bausch & Lomb (Australia) Pty Ltd (2004) 62 IPR 71
Rescare Ltd v Anaesthetic Supplies Pty Ltd (unreported, Gummow J, 4 March 1993)
Smith Kline & French Laboratories Limited v Evans Medical Limited [1989] 1 FSR 561
Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Limited (No 2) (1997) 74 FCR 306
Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Ltd (No 3) (1997) AIPC 91-366
Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Ltd (unreported, Sundberg J, 12 November 1997)

Aldous W, Young D, Watson A, Thorley S, Terrell on the Law of Patents (13th ed, Sweet & Maxwell, 1982)
Thorley S, Miller R, Burkill G, Birss C, Terrell on the Law of Patents (15th ed, Sweet & Maxwell, 2000)

Dates of hearing: 18, 19, 20 June 2012
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 233
Counsel for the Applicant (Bayer Pharma Aktiengesellschaft): Mr D Shavin QC and Ms HMJ Rofe
Solicitor for the Applicant (Bayer Pharma Aktiengesellschaft): Davies Collison Cave Law Pty Ltd
Counsel for the Respondents: Ms AH Bowne SC and Ms MV McCarthy
Solicitor for the Respondents: Middletons
Counsel for the Opponent (Eremad Pty Limited): Mr DK Catterns QC
Solicitor for the Opponent (Eremad Pty Limited): Ashurst Australia

IN THE FEDERAL COURT OF…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2012] FCA 1510
Decision Date

CaseChat Overview and Summary

Bayer Pharma Aktiengesellschaft, the owner of an Australian patent for a pharmaceutical combination, sought amendments to the patent claims to include specific dissolution tests for the active agents. The respondents, Generic Health Pty Ltd, opposed the amendments. The matter was heard by the Federal Court of Australia, which had to determine whether the discretion under Section 105 of the Patents Act 1990 should be exercised in favour of Bayer Pharma.

The key legal issue was whether Bayer Pharma's application for patent amendments should be allowed, considering the principles of unreasonable delay, covetous claiming, and unfair advantage. The respondents argued that the application was untimely and that granting the amendments would confer an unfair advantage. Bayer Pharma, on the other hand, contended that the amendments were necessary to correct a drafting error and that there was no unreasonable delay.

The Court found that Bayer Pharma had not acted unreasonably in delaying the application for amendments. The Court concluded that the amendments were necessary to correct a drafting error and did not constitute covetous claiming or provide an unfair advantage to Bayer Pharma. The Court also noted that the infringement of the patent by the respondents was ongoing, and the amendments would not change the nature of the infringement claims. Therefore, the discretion under Section 105 of the Act should be exercised in favour of Bayer Pharma.

The Court ordered the patent to be amended as requested by Bayer Pharma, extended the time for appeal against the decision, and stayed the orders pending the publication of the Court's reasons.

Orders

Orders of the court

1. Pursuant to s 105(1) of the Patents Act 1990 (Cth) (the Act), Australian Patent No. 780330 entitled “Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive” be amended in the manner set out in the annexure to the interlocutory application dated 13 April 2012 (the interlocutory application).

2. The time for filing any application for leave to appeal from the orders made by the Court today pursuant to s 105(1) of the Act be extended until the date which is 14 days after the publication of the Court’s reasons for judgment on the interlocutory application.

3. The orders made by the Court today pursuant to s 105(1) of the Act be stayed pending the date which is 14 days after the publication of the Court’s reasons for judgment on the interlocutory application.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

No objection has been raised by the respondents or Eremad that the amendments, as sought, do not satisfy the legal requirements of s 102 of the Act. The only issue is whether the discretion to allow the amendments under s 105 of the Act should be exercised favourably to Bayer Pharma as patentee.THE EVIDENCE The evidence in support of Bayer Pharma’s application to amend was given principally by Andreas Broesamle. Dr Broesamle is employed within the Bayer group of companies as Senior Patent Counsel. In that role he manages the filing and prosecution of a number of patents within Bayer Pharma’s worldwide patent portfolio. Since 2000 his involvement in patents covering drospirenone has been the substantial part of his work, which also includes the enforcement and defence of patents within Bayer Pharma’s patent portfolio. Dr Broesamle’s evidence in chief was given in the form of a substantial affidavit which included a large number of documents detailing the prosecution history of the application for the Australian patent and other corresponding patent applications. Dr Broesamle was cross‑examined on his affidavit by the respondents and by Eremad. The evidence in support of Bayer Pharma’s application also included affidavits given by John Sopp and Anthony Zelano. Mr Sopp and Mr Zelano are United States patent attorneys. Mr Zelano is a partner in the firm of Millen, White, Zelano & Branigan, P.C. (MWZB). Mr Sopp is employed by MWZB. Mr Sopp was responsible for handling the prosecution of US Patent Application No. 09/654,227 (the US application) – to which I make further reference below – together with Mr Zelano. Neither Mr Sopp nor Mr Zelano were required for cross-examination. Finally, Bayer Pharma adduced affidavit evidence from its solicitor, Ian Pascarl. Mr Pascarl is a partner in the firm of Davies Collison Cave (DCC). Mr Pascarl was not required for cross-examination. The respondents adduced evidence from Joseph Schieber. Mr Schieber is a principal in the firm of Watermark Patent and Trade Mark Attorneys. He is a registered Australian patent attorney as well as a qualified German patent attorney and a qualified European patent attorney. Mr Schieber’s evidence in chief was given in the form of an affidavit which commented on a number of aspects of Dr Broesamle’s affidavit. Mr Schieber was cross‑examined on his affidavit. Eremad adduced affidavit evidence from Andrew Rankine, a solicitor employed by Ashurst Australia. This affidavit exhibited a number of documents on which Eremad has placed reliance. Mr Rankine was not required for cross-examination.PATENT PROSECUTION HISTORY: CORRESPONDING PATENTS AND APPLICATIONSThe PCT application As I have noted, the PCT application was filed on 31 August 2000. Claims 7 to 9 incorporated dissolution tests, in the following form: 7.A composition according to any of the preceding claims wherein the pharmaceutically acceptable carrier or excipient is selected so as to promote rapid dissolution of the first and second active agents.8.A composition according to any of the preceding claims wherein at least 70% of the first and second active substance are released within 30 minutes of administration thereof.9.A composition according to claim 8, wherein at least 80% of the first and second active agents are released within 20 minutes of administration thereof.

Decision

Reasons for decision

Does the fact that, in the present case, Bayer Australia also sent the facsimile transmission of 17 February 2012 make a difference? In my view, it does not. Bayer Pharma and Bayer Australia were entitled to inform pharmacists of their joint position that the supply of the Isabelle product was an infringement of the Australian patent and that they had commenced a proceeding to vindicate their asserted rights. If the respondents were infringing the Australian patent by supplying the Isabelle product, then so too were the pharmacists who were re-supplying that product. Apart from acting to protect their respective commercial interests in seeking the continued sale by pharmacists of the Yasmin product, Bayer Pharma and Bayer Australia were also entitled to act to protect their respective legal interests, including in relation to obtaining pecuniary relief arising from any infringement of the Australian patent that might be found. To this end it was legitimate for Bayer Pharma and Bayer Australia to give direct notice to pharmacists of the assertion of their rights in the principal proceeding: see ss 122(1), 122(1A)(c) and 123 of the Act. This was done by both the facsimile of 25 January 2012 and the facsimile of 17 February 2012. Having regard to the nature and form of the particular amendments sought in the present application, it was not incumbent on either Bayer Pharma or Bayer Australia to also inform pharmacists of the fact that Bayer Pharma would be seeking those amendments in the principal proceeding. Furthermore, there is no evidence to suggest that Bayer Pharma or Bayer Australia would not continue to pursue their causes of action for infringement in the principal proceeding, even if the amendments which Bayer Pharma has sought are not granted.CONCLUSION I am satisfied that it is appropriate in all the circumstances that the discretion under s 105 of the Act be exercised in favour of granting the amendments that are sought. On the question of costs, this Court has proceeded on an acceptance of the proposition that an opponent is entitled to its costs, even if the amendments are allowed over the opposition: Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Ltd (unreported, Sundberg J, 12 November 1997); Gambro Pty Ltd v Fresenius Medical Care South East Asia Pty Ltd [2000] FCA 407; Apotex Pty Ltd v Les Laboratoires Servier (No 3) [2009] FCA 1069 at [5]; CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 3) [2010] FCA 1279 at [4]. In the present case the respondents and Eremad each placed reliance on that proposition. Eremad, in particular, developed a number of submissions that address the question of costs. Bayer Pharma also accepted that costs would ordinarily be paid by the patentee. In the course of oral submissions, however, it suggested (without development) that there may be other features in this case that would warrant a different approach. It submitted that costs should be dealt with after the making of substantive orders in the application. Those orders were made on 14 December 2012. At the time of making the orders, I said that I would deal with the question of costs when publishing these reasons.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.